Can Weight-Loss Drugs Like GLP-1s Help People Drink Less? New Study Explains

GLP-1 receptor agonists such as Ozempic and Wegovy have transformed the treatment of obesity and type 2 diabetes.

Now, scientists believe these blockbuster drugs may have another surprising benefit: helping people reduce alcohol consumption and lowering the risk of substance use disorders.

Although GLP-1 medications are not approved for treating addiction, a growing number of studies suggest they may curb cravings by acting on the brain’s reward pathways. The findings have fuelled interest among researchers searching for new ways to tackle alcohol dependence, a condition that affects millions worldwide.

Still, experts caution that the evidence remains preliminary, and the drugs should not be viewed as a treatment for addiction until large clinical trials confirm their effectiveness.

HOW DO GLP-1 DRUGS WORK?

GLP-1 receptor agonists mimic the hormone glucagon-like peptide-1, which helps regulate blood sugar, slows digestion and promotes a feeling of fullness. While they were originally developed for diabetes, they have become widely used for weight loss because they suppress appetite.

Researchers now believe the same biological mechanisms may also influence the brain’s reward system, particularly dopamine signalling, which plays a major role in cravings for food, alcohol and other addictive substances.

CAN THEY HELP PEOPLE DRINK LESS?

Early evidence points in that direction.

Several human studies have found that people taking GLP-1 medications report drinking less alcohol, while animal studies have consistently shown reductions in alcohol intake after treatment. Other observational research has also linked GLP-1 therapy with a lower likelihood of developing alcohol use disorder.

Scientists stress, however, that these studies show an association rather than proving the drugs directly reduce alcohol consumption.

WHAT DOES THE LATEST RESEARCH SAY?

A 2026 study from the University of Texas at El Paso analysed health data from more than 142,000 adults with obesity or type 2 diabetes. Nearly 20,000 participants had been prescribed GLP-1 medications.

Researchers found that patients taking GLP-1 drugs had significantly lower odds of developing several substance use disorders compared with those not receiving the medications:

74% lower odds of alcohol use disorder
69% lower odds of opioid use disorder
68% lower odds of nicotine use disorder
75% lower odds of cocaine use disorder

The findings suggest that GLP-1 medications may influence multiple addiction-related pathways rather than alcohol use alone.

WHY COULD THEY REDUCE CRAVINGS?

Scientists believe the answer lies in the brain’s reward circuitry.

While addiction research has traditionally focused on dopamine-rich regions such as the ventral tegmental area and nucleus accumbens, newer studies highlight the lateral septum—a brain region with a high concentration of GLP-1 receptors.

Activating these receptors may reduce the brain’s response to rewarding stimuli, dampening cravings and weakening the mental cues that often trigger addictive behaviours.

WHAT ARE THE LIMITATIONS?

Despite the encouraging results, researchers emphasise that GLP-1 medications are not yet a proven treatment for addiction.

The UTEP study was observational, meaning it identified a relationship but could not establish cause and effect. Randomised clinical trials are still needed to determine whether the drugs directly reduce alcohol use, identify the patients most likely to benefit and evaluate their long-term safety in addiction treatment.

Cost, side effects and access also remain significant barriers, and not everyone experiences the same response to GLP-1 therapy.

THE TAKEAWAY

GLP-1 medications are opening an intriguing new avenue in addiction research, raising the possibility that drugs originally designed for diabetes and obesity could also help people struggling with alcohol and substance use disorders.

For now, however, the evidence is promising rather than conclusive. People should not use GLP-1 medications solely to reduce alcohol consumption without medical advice, as researchers continue to investigate whether the early findings translate into effective addiction treatment.